Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Posted by on May 14th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

  • On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.19, for a total value of $691,900.00.
  • On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total value of $635,000.00.
  • On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00.
  • On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total value of $702,100.00.
  • On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $70.03 on Thursday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 3.66. The stock has a 50-day moving average of $65.71 and a 200-day moving average of $68.63. The company has a market cap of $8.30 billion, a PE ratio of 25.19, a P/E/G ratio of 0.29 and a beta of 0.89. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period last year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in HALO. Empowered Funds LLC bought a new position in Halozyme Therapeutics in the 1st quarter valued at about $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics in the 1st quarter valued at about $195,000. Hsbc Holdings PLC lifted its position in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on HALO shares. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. HC Wainwright raised their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Check Out Our Latest Analysis on Halozyme Therapeutics

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

  • Positive Sentiment: Halozyme beat Q1 estimates, with revenue rising about 42% year over year to $376.7 million and EPS coming in above expectations, helping support investor confidence in the company’s growth outlook. Article Title
  • Positive Sentiment: The company also highlighted a new $1 billion share repurchase authorization and reiterated full-year guidance, which can be viewed as a signal of management confidence and a potential support for the share price. Article Title
  • Positive Sentiment: Halozyme announced a global collaboration and license agreement with GSK for its ENHANZE drug-delivery technology, potentially expanding its long-term royalty stream if partnered programs progress. Article Title
  • Neutral Sentiment: Morgan Stanley trimmed its price target on Halozyme to $93 from $96, but kept an overweight rating, so the note was not a major negative for the stock. Article Title
  • Negative Sentiment: CEO Helen Torley disclosed two recent stock sales totaling 30,000 shares under a pre-arranged 10b5-1 plan, which may weigh on sentiment even though the trades were planned in advance. Article Title

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Featured Articles

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.